If you are in crisis: Samaritans 116 123 (free, 24/7), text SHOUT to 85258, NHS 111, or attend your nearest A&E.
Finasteride and persistent sexual dysfunction: is it real?
MHRA RECOGNISED
Part of our overview of finasteride side effects, with every symptom guide in one place.
What the regulator says
The title of the MHRA Drug Safety Update of 29 April 2024 is verbatim: "Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)". The persistence after discontinuation is part of the regulator's official recognition. The 11 May 2026 update strengthened these warnings. The April 2024 update cited 426 Yellow Card reports of sexual dysfunction with finasteride (1 mg and 5 mg) up to 5 April 2024, the first in November 1992. In almost half of these reports the outcome was recorded as "not recovered" or "not resolved". This is a count of spontaneous reports to the regulator over more than 30 years, not a rate, because the number of people taking finasteride is not known from the reports alone.
Source: MHRA Drug Safety Update
In plain English
Persistent sexual dysfunction after stopping finasteride (commonly called "post-finasteride syndrome" or PFS in patient communities) is recognised in UK regulatory wording. The MHRA does not use "PFS" as a formal term but does acknowledge that in a small number of cases sexual side effects (reduced libido, erectile dysfunction, ejaculation disorders) have been reported to persist after the medication is stopped. There is no current diagnostic test, and the mechanism is still under investigation.
How long does it last
The UK product information for finasteride 1 mg lists "persistence of sexual dysfunction (decreased libido, erectile dysfunction and ejaculation disorder)" after discontinuation among the effects reported since the medicine was marketed, but it gives no figure for how long it lasts or how often it happens. The natural history of persistent post-discontinuation sexual dysfunction is poorly characterised. Some patients report gradual improvement over many months; others report sustained symptoms. There is currently no licensed treatment for the persistent form. Active research is ongoing.
The 426 Yellow Card reports quoted above were received up to 5 April 2024; the separate figure of 170 reports of suicidal ideation (1994 to 31 May 2025) comes from the May 2026 update and is a different dataset. Our MHRA safety updates page sets out the chronology, our article on the 2024 and 2026 MHRA updates explains what changed between them, and the glossary entry on post-finasteride syndrome gives the short definition.
What to do if it happens to you
If sexual side effects do not resolve after stopping finasteride: report via the MHRA Yellow Card scheme; consult your prescriber and GP; consider referral to specialist sexual medicine or endocrinology; document the symptoms and timeline because this informs both your care and the regulator's ongoing review.
When to seek urgent care
If persistent sexual dysfunction is accompanied by depression, suicidal thoughts, or severe mental distress, contact Samaritans on 116 123 (free, 24/7), NHS 111, or attend your nearest A&E immediately.